Wikipedia

Joseph F. Holson

Joseph F. Holson, an American scientist, business executive, and educator in the disciplines of toxicology and product development, served as President of WIL Research Laboratories for 20 years (1988-2008). He is known for his contributions to the fields of developmental and reproductive toxicology (DART),[1] pharmacokinetics,[2][3] and risk assessment,[4] including extensive experience with study design, data interpretation,[1][5] and interspecies extrapolation of health effects data.[6][7] He has served in numerous U.S. EPA/FDA advisory committees and as an expert toxicology witness. He was elected to two National Academy of Sciences toxicology committees.[8][9] Dr. Holson is an editor and author of the textbook Regulatory Toxicology[10] and an author of two significant chapters in the textbook Developmental and Reproductive Toxicology: A Practical Approach, Second Edition.[1][5] Two of his peer-reviewed articles were recognized by the Risk Assessment Specialty Section of the Society of Toxicology as the Outstanding Published Papers Demonstrating an Application of Risk Assessment.[3][4] He is the first author to receive this award in consecutive years for publications produced with two separate sets of coauthors.

Joseph F. Holson
Born
Joseph Franklin Holson
NationalityAmerican
Other namesJoe Holson
Alma materEast Carolina University
University of Cincinnati College of Medicine
Scientific career
FieldsToxicologist
InstitutionsNational Center for Toxicological Research
WIL Research Laboratories
ThesisRelative Transport Roles of Chorioallantic and Yolk Sac Placentae on the 12th and 13th Days of Gestation (1974)
Doctoral advisorJames G. Wilson

Education

edit

Joseph Holson received his Doctorate in Physiology in 1973 from the University of Cincinnati College of Medicine, having studied under the direction of Dr. James G. Wilson in the disciplines of developmental toxicology and research pediatrics. His doctoral research investigated the relative transport capabilities of chorioallantoic and yolk sac placentae during organogenesis in the rat.[11] Prior to his doctoral training, he earned a B.S. (1967) and M.S. (1969)[12] in Biology from East Carolina University (receiving the Poteat Award for his research on the teratogenicity of LSD).[13] He also completed a Traineeship in Reproductive Physiology at Louisiana State University in Baton Rouge, Louisiana, in 1970.

Career

edit

National Center for Toxicological Research

edit

Dr. Holson began his professional career in 1973 with the U.S. FDA/EPA-sponsored National Center for Toxicological Research (NCTR) in Little Rock, Arkansas, as a reproductive toxicologist. He became the Division Director in 1975 and organized a multidisciplinary research program,[14] which became one of the nation's major federally sponsored research groups in reproductive toxicology. For the next five years, he directed the teratology and developmental toxicology research programs of the National Toxicology Program (NTP), which focused on biochemical and physiological causes of birth defects, pharmacokinetics, postnatal functional evaluations, and mechanistic studies. While at NCTR, Holson also was instrumental in developing the FDA Good Laboratory Practice (GLP) regulations and organized and wrote the first FDA training program for GLP inspectors.

During his tenure at NCTR, he also served as Assistant Professor of Physiology in the Interdisciplinary Toxicology Training Program at the University of Arkansas School of Medicine in Little Rock, Arkansas. In this capacity, he developed and taught the first graduate-level regulatory toxicology course in the country, served on PhD student committees, and was a member of the admissions committee and policy council.

Science Applications International Corporation

edit

Dr. Holson joined Science Applications International Corporation (SAIC) in La Jolla, California during March 1980 to establish research and development and chemical testing programs in toxicology. For the next five years, he directed SAIC’s toxicology division, which included an active reproductive toxicology research emphasis. In 1983, he was elected to SAIC's Executive Science and Technology Council. During his time at SAIC, he served as an adjunct lecturer in toxicology for the Toxicology Training Program at the University of Arizona and the Graduate Program in Public Health at San Diego State University.

Biomedical Research Institute of America

edit

From 1985 through 1986, he served as President of Biomedical Research Institute of America in La Jolla, California and as an independent consultant in toxicology. From 1980-1986, he also served as a member of the Board of Directors and Secretary for the San Diego Biomedical Research Institute.

WIL Research Laboratories

edit

In March 1987, Dr. Holson was appointed Vice President and Director of Developmental and Reproductive Toxicology at WIL Research Laboratories, Inc., in Ashland, Ohio. In August 1988, he was promoted to President and Director of WIL Research. During the next 20 years, he was responsible for all fiduciary and scientific aspects of the company’s operations.[15] He remained scientifically active by serving as a study director upon special request, selectively reviewing data and reports, advising sponsors regarding toxicologic and product development issues, serving as a consultant to federal agencies, publishing scientific papers, giving presentations to various community and scientific organizations, and lecturing at Ashland University. He also served on Ashland University’s Science Advisory Board (1990-2008) and Board of Trustees (1993-1998), as well as Pfizer's Advisory Panel for Developmental and Reproductive Toxicology and Johnson & Johnson's Advisory Panel for Pediatric-Approved Pharmaceuticals.

Under Joe Holson's leadership, WIL Research grew from approximately 30 employees and negative profitability into a dynamic contract research organization employing more than 600 individuals, with an 18% compound annual growth rate and nearly $40 million annual EBITDA. This success was attributed to the internationally recognized scientific prowess of WIL's staff, the company's study director-centric business model (which viewed each study director as an individual business unit with scientific, project management, and marketing responsibilities), and internally developed innovations such as the industry's first protocol-driven toxicology data management software system.[16] Holson emphasized direct scientist-to-scientist interaction as much as possible across the entire scope of each project, which gained WIL Research numerous accolades from its clients.[17]

After nearly two decades of sustained organic growth, Holson led WIL Research through a period of private capital-financed expansion, beginning with a management buyout (in partnership with Behrman Capital[18]) and formation of a holding company (WRH) in 2004. The expansion continued with acquisitions in the U.S. and Europe,[19] culminating in the $500 million sale of WRH to American Capital, Ltd. (NASDAQ:ACAS) in 2007. After the sale to ACAS, he served as Vice President and Chief Scientific Officer of the global entity while continuing to serve as President and Director of WIL Research Laboratories in Ashland, Ohio until his retirement from active management duties in November 2008. He served on the Board of Directors of WRH from its inception in 2004 until February 2009.

Research highlights

edit

Joe Holson's research career has spanned a diverse range of test agents using a variety of experimental animal models and human studies. Building upon the foundational principles of teratology expounded upon by his doctoral advisor, James G. Wilson, his work has emphasized comparative and holistic approaches to problem-solving in the field of developmental and reproductive toxicology. These approaches included extensive collaboration between experimental toxicologists and epidemiologists, advancements in experimental design (e.g., use of replicates and unbalanced study designs) and biostatistics (e.g., use of statistical power calculations), and robust assessments of reliability and animal-human concordance of experimental toxicity findings.[8]

Early in Holson's career, while at NCTR, he led studies that assessed the developmental toxicity of FD&C Red No. 2,[20][21][22] an amaranth dye, and the herbicide 2,4,5‐T (a component of Agent Orange).[23][24][25] The FD&C Red No. 2 study was a multi-laboratory collaborative effort between industry, U.S. FDA, and NCTR, while the 2,4,5-T study was a large-scale multireplicated study in various strains/stocks of mice that included replicated test groups, at least four dose levels per replicate, use of multiple stocks/strains of animals to obtain an estimate of the range in sensitivities due to genotype, complete maternal pathology, and fetal histopathology and teratological evaluation. In a follow-up statistical analysis of these data, it was calculated that 805 litters per dose group would be necessary to detect a 5% increase in embryo resorption, suggesting that no standard regulatory study is adequately capable of evaluating the dose-response threshold at low response rates.[26][27] Based on these results, Holson recommended that U.S. FDA include a similar approach to standardize the statistical resolving power of tests relative to known interlaboratory and interspecies endpoint variability and variances.[26]

Holson was also among the first developmental toxicologists to quantitatively evaluate the "litter effect" of studies in which fetal endpoints were assessed after the maternal animal was dosed.[28] Although litter-based statistical analyses had been conducted for body weight and survival parameters, Holson insisted that litter-based corrections should also be used for fetal malformations and variations.[1]

Based on his early work, Holson was among the first teratology researchers to assert that the various endpoints of developmental toxicity studies (intrauterine growth retardation, malformations [birth defects], functional impairment, and death) in fact constituted a continuum of responses rather than discrete outcomes, which led him to conclude that human manifestations of teratogenicity across exposure levels were most commonly multiple outcomes.[1][7] Throughout his career Holson argued consistently that developmental toxicity must be viewed holistically, not simply as a group of disparate anatomical, functional, and postnatal defects, before such data can be effectively used to derive a complete estimate of human risks.

Holson was among the first to recognize that more emphasis needed to be placed on pharmacokinetic evaluations within developmental and reproductive toxicity studies in order to quantify the internal exposure to xenobiotics.[7] His team at NCTR conducted the first series of studies designed to assess the feasibility of using pharmacokinetics to improve the design, interpretation, and extrapolation of developmental toxicity studies, in an attempt to develop methods for predicting the magnitude of endpoints in teratology and to show how interlitter variability and inter-strain and inter-species differences could be better interpreted and accounted for based on differences in the handling of a compound. Throughout his career he emphasized the use of pharmacokinetic determinations as a necessary component of developmental, reproductive, and nonclinical juvenile toxicity studies.[1][5]

Holson was also the first to apply the principle of comparative ontogeny of development (physiologic age) between organ systems in various species to the interpretation of developmental, reproductive, and pediatric toxicology data.[1][5]

Throughout his career, Holson served as a key advisor to numerous product development programs (INDs, NDAs, TCSA consent orders, FIFRA registrations and international product registrations) and was the principal investigator in more than 600 safety assessment studies. In these studies he emphasized his longstanding principles of holistic evaluation of data, inclusion of pharmacokinetic endpoints where possible, robust and creative experimental designs, determination of the statistical power of the study relative to known variability in endpoints, and cognizance of comparative ontogeny of development.[1][5] In addition to LSD, FD&C Red No. 2, and 2,4,5-T, he was instrumental in significant developmental, reproductive, and/or nonclinical juvenile toxicity assessments of mirex,[2][29] inorganic arsenic,[4][30][31][32][33][34][35][36][37] nelfinavir (Viracept, an antiretroviral drug used to treat AIDS),[38][39] fluoxetine (Prozac),[40][41] two silicon-based ingredients found in breast implants and numerous personal care products (D4 and D5),[42][43][44] methyl iodide,[45][46] and HBOC-201 (a bovine hemoglobin-based oxygen carrier).[47][48][49]

Retirement

edit

After retiring from active duties at WIL Research, Dr. Holson focused on conservation efforts on his 90-acre farm outside Ashland, Ohio. Since 1994, when he began to plant native prairie grasses and several thousand trees, he allowed the bulk of the property to gradually return to a natural state as a conservation habitat supported by Ohio's Conservation Reserve Program, including development of a 10-acre wildflower area designated as a pollinator habitat. He also maintains 45 acres of mature hardwood forest. This overall effort has facilitated Holson's personal study of conservation and animal behavior, including various flora and fauna.

Felony Drug & Sex Offender Charges

In August 2009, Dr. Holson plead guilty to the "possession of cocaine and complicity involving the illegal use of a minor in nudity-oriented material or performance",[50] which required him to register as a Tier I sex offender. He later unsuccessfully appealed to withdraw these pleas.[51]

Footnotes

edit
  1. ^ a b c d e f g h Holson, Joseph F.; Nemec, Mark D.; Stump, Donald G.; Kaufman, Lewis E.; Lindstrom, Pia; Varsho, Bennett J. (2006). "Significance, Reliability, and Interpretation of Developmental and Reproductive Toxicity Study Findings". In Hood, R.D. (ed.). Developmental and Reproductive Toxicology: A Practical Approach, Second Edition. Boca Raton: Taylor and Francis. pp. 329–424. ISBN 9781420040548.
  2. ^ a b Byrd, Richard A.; Young, John F.; Kimmel, Carole A.; Morris, Manford D.; Holson, Joseph F. (1982-11-01). "Computer simulation of mirex pharmacokinetics in the rat". Toxicology and Applied Pharmacology. 66 (2): 182–192. doi:10.1016/0041-008X(82)90283-6. PMID 7164097.
  3. ^ a b Sweeney, L. M.; Tyler, T. R.; Kirman, C. R.; Corley, R. A.; Reitz, R. H.; Paustenbach, D. J.; Holson, J. F.; Whorton, M. D.; Thompson, K. M. (2001-07-01). "Proposed Occupational Exposure Limits for Select Ethylene Glycol Ethers Using PBPK Models and Monte Carlo Simulations". Toxicological Sciences. 62 (1): 124–139. doi:10.1093/toxsci/62.1.124. ISSN 1096-6080. PMID 11399800.
  4. ^ a b c Holson, Joseph F.; Desesso, John M.; Jacobson, Catherine F.; Farr, Craig H. (2000-07-01). "Appropriate use of animal models in the assessment of risk during prenatal development: An illustration using inorganic arsenic". Teratology. 62 (1): 51–71. doi:10.1002/1096-9926(200007)62:1<51::aid-tera10>3.3.co;2-k. ISSN 1096-9926. PMID 10861633.
  5. ^ a b c d e Beck, Melissa J.; Padgett, Eric L.; Bowman, Christopher J.; Wilson, Daniel T.; Kaufman, Lewis E.; Varsho, Bennett J.; Stump, Donald G.; Nemec, Mark D.; Holson, Joseph F. (2006). "Nonclinical Juvenile Toxicity Testing". In Hood, R.D. (ed.). Developmental and Reproductive Toxicology: A Practical Approach, Second Edition. Boca Raton: Taylor and Francis. pp. 263–327. ISBN 9781420040548.
  6. ^ White, C.G.; Holson, J.F.; Young, J.F. (1981). Extrapolation Models in Teratogenesis (NCTR Final Report for Experiment No. 281). Jefferson, AR: National Center for Toxicological Research.
  7. ^ a b c Kimmel, C.A.; Holson, J.F.; Hogue, C.J.; Carlo, G.L. (1984). Reliability of Experimental Studies for Predicting Hazards to Human Development (NCTR Final Report for Experiment No. 6015). Jefferson, AR: National Center for Toxicological Research.
  8. ^ a b NRC (National Research Council) Committee on Developmental Toxicology (E. M. Faustman, J. C. Gerhart, N. A. Brown, G. P. Daston, M. C. Fishman, J. F. Holson, H. B. W. M. Koëter, A. P. Mahowald, J. M. Manson, R. K. Miller, P. E. Mirkes, D. W. Nebert, D. M. Noden, V. E. Papaioannou, G. C. Schoenwolf, F. Welsch, W. B. Wood) (2000). Scientific Frontiers in Developmental Toxicology and Risk Assessment. National Academy Press. ISBN 978-0-309-07086-7.{{cite book}}: CS1 maint: multiple names: authors list (link)
  9. ^ NRC (National Research Council) Subcommittee on Reproductive and Developmental Toxicology (C. A. Kimmel, G. M. Buck, M. H. Feuston, P. M. D. Foster, J. M. Friedman, J. F. Holson, C. L. Hughes, J. A. Moore, B. A. Schwetz, A. R. Scialli, W. J. Scott, C. V. Vorhees, B. R. Zirkin) (2001). Evaluating Chemical and Other Agent Exposures for Reproductive and Developmental Toxicity. National Academy Press. ISBN 978-0-309-07316-5.{{cite book}}: CS1 maint: multiple names: authors list (link)
  10. ^ Chengelis, C.P.; Holson, J.F.; Gad, S.C., eds. (1995). Regulatory Toxicology. New York: Raven Press Ltd. ISBN 978-0781701914.
  11. ^ Holson, Joseph (1974). Relative Transport Roles of Chorioallantic and Yolk Sac Placentae on the 12th and 13th Days of Gestation (Doctoral Dissertation). University of Cincinnati. OCLC 981288.
  12. ^ Holson, Joseph F. (1970). Teratogenic Potential of D-Lysergic Acid Diethylamide (delysid) in the Albino Rat (Master's Thesis). East Carolina University.
  13. ^ "Proceeding and Abstracts from the Sixty-Sixth Annual Meeting of the North Carolina Academy of Science, May 2-3, 1969, at Wilmington, N.C." Journal of the Elisha Mitchell Society. 1969. Retrieved 2 September 2015.
  14. ^ National Research Council (1977). The National Center for Toxicological Research: The Evaluation of Its Program. National Academy of Sciences. pp. 146–147.
  15. ^ "Nemec promoted to lead WIL Research Labs". Ashland Times. Retrieved 2017-09-11.
  16. ^ "You're in Good Company in Ohio: Featuring WIL Research Laboratories Inc". Forbes. 18 December 1995.
  17. ^ "WIL Research Labs to expand". Ashland Times-Gazette. 30 July 2003.
  18. ^ https://www.sec.gov/Archives/edgar/data/43362/000110465904029322/a04-11133_1ex99di.htm [bare URL]
  19. ^ "Notox acquired by WIL Research".
  20. ^ Collins, T. F. X.; Ruggles, D. I.; Holson, J. F. Jr.; Schumacher, H.; Gaylor, D. W.; Kennedy, G. L. Jr. (1976-05-01). "Teratological evaluation of FD&C red no. 2—A collaborative government-industry study. I. Introduction, experimental materials, and procedures". Journal of Toxicology and Environmental Health. 1 (5): 851–856. Bibcode:1976JTEHA...1..851C. doi:10.1080/15287397609529385. ISSN 0098-4108. PMID 58068.
  21. ^ Holson, J. F. Jr.; Schumacher, H. J.; Gaylor, D. W.; Gaines, T. B.; Collins, T. F. X. (1976-05-01). "Teratological evaluation of FD&C red no. 2—A collaborative government-industry study. IV. NCTR's study". Journal of Toxicology and Environmental Health. 1 (5): 867–874. Bibcode:1976JTEHA...1..867H. doi:10.1080/15287397609529388. ISSN 0098-4108. PMID 1271492.
  22. ^ Holson, J. F. Jr.; Gaylor, D. W.; Schumacher, H. J.; Collins, T. F. X.; Ruggles, D. I.; Keplinger, M. L.; Kennedy, G. L. Jr. (1976-05-01). "Teratological evaluation of FD&C red no. 2—A collaborative government-industry study. V. Combined findings and discussion". Journal of Toxicology and Environmental Health. 1 (5): 875–885. Bibcode:1976JTEHA...1..875H. doi:10.1080/15287397609529389. ISSN 0098-4108. PMID 1271493.
  23. ^ Nelson, C. J.; Holson, J. F.; Green, H. G.; Gaylor, D. W. (1979-06-01). "Retrospective study of the relationship between agricultural use of 2,4,5-T and cleft palate occurrence in Arkansas". Teratology. 19 (3): 377–383. doi:10.1002/tera.1420190315. ISSN 1096-9926. PMID 473090.
  24. ^ Holson, J. F.; Gaines, T. B.; Nelson, C. J.; Laborde, J. B.; Gaylor, D. W.; Sheehan, D. M.; Young, J. F. (1992-08-01). "Developmental Toxicity of 2,4,5-Trichlorophenoxyacetic Acid (2,4,5-T) I. Multireplicated Dose-Response Studies in Four Inbred Strains and One Outbred Stock of Mice". Toxicological Sciences. 19 (2): 286–297. doi:10.1093/toxsci/19.2.286. ISSN 1096-6080. PMID 1516787.
  25. ^ NELSON, C (1992-01-01). "Developmental toxicity of 2,4,5-trichlorophenoxyacetic acid (2,4,5-T) II. Multireplicated dose-response studies with technical and analytical grades of 2,4,5-T in four-way outcross mice". Fundamental and Applied Toxicology. 19 (2): 298–306. doi:10.1016/0272-0590(92)90164-d. PMID 1516788.
  26. ^ a b Nelson, C. J.; Holson, J. F. (1978-10-01). "Statistical analysis of teratologic data: problems and advancements". Journal of Environmental Pathology and Toxicology. 2 (1): 187–199. ISSN 0146-4779. PMID 722220.
  27. ^ Klaassen, Curtis D., ed. (2013). Casarett & Doull's Toxicology the Basic Science of Poisons (8th ed.). McGraw-Hill Education. p. 491. ISBN 978-0-07-176923-5.
  28. ^ Holson, J. F.; Scott, W. J.; Gaylor, D. W.; Wilson, J. G. (1976-10-01). "Reduced interlitter variability in rats resulting from a restricted mating period, and reassessment of the "Litter effect"". Teratology. 14 (2): 135–141. doi:10.1002/tera.1420140204. ISSN 1096-9926. PMID 982310.
  29. ^ Byrd, Richard A.; Kimmel, Carole A.; Morris, Manford D.; Holson, Joseph F.; Young, John F. (1981-01-01). "Altered pattern of prenatal toxicity in rats due to different treatment schedules with mirex". Toxicology and Applied Pharmacology. 60 (2): 213–219. doi:10.1016/0041-008x(91)90225-4. PMID 7281184.
  30. ^ DeSesso, JohnM; Jacobson, CatherineF; Scialli, AnthonyR; Farr, CraigH; Holson, JosephF (1998-07-01). "An assessment of the developmental toxicity of inorganic arsenic 1". Reproductive Toxicology. 12 (4): 385–433. doi:10.1016/S0890-6238(98)00021-5. PMID 9717692.
  31. ^ Nemec, MarkD; Holson, JosephF; Farr, CraigH; Hood, RonaldD (1998-11-06). "Developmental toxicity assessment of arsenic acid in mice and rabbits". Reproductive Toxicology. 12 (6): 647–658. doi:10.1016/S0890-6238(98)00053-7. PMID 9875698.
  32. ^ Holson, J. F.; Stump, D. G.; Ulrich, C. E.; Farr, C. H. (1999-09-01). "Absence of prenatal developmental toxicity from inhaled arsenic trioxide in rats". Toxicological Sciences. 51 (1): 87–97. doi:10.1093/toxsci/51.1.87. ISSN 1096-6080. PMID 10496680.
  33. ^ Holson, Joseph F.; DeSesso, John M.; Scialli, Anthony R.; Farr, Craig H. (1999-01-01). Calderon, Willard R. ChappellCharles O. AbernathyRebecca L. (ed.). Inorganic Arsenic and Prenatal Development: A Comprehensive Evaluation for Human Risk Assessment. Oxford: Elsevier Science Ltd. pp. 183–190. doi:10.1016/b978-008043648-7/50021-2. ISBN 978-0-08-043648-7.
  34. ^ Jacobson, Catherine F.; Stump, Donald G.; Nemec, Mark D.; Holson, Joseph F.; DeSesso, John M. (1999-09-01). "Appropriate Exposure Routes and Doses in Studies Designed to Assess Developmental Toxicity: A Case Study of Inorganic Arsenic". International Journal of Toxicology. 18 (5): 361–368. doi:10.1080/109158199225279. ISSN 1091-5818. S2CID 72950627.
  35. ^ Stump, D.g.; Holson, J.f.; Fleeman, T.l.; Nemec, M.d.; Farr, C.h. (1999-11-01). "Comparative effects of single intraperitoneal or oral doses of sodium arsenate or arsenic trioxide during in utero development". Teratology. 60 (5): 283–291. doi:10.1002/(sici)1096-9926(199911)60:5<283::aid-tera9>3.0.co;2-7. ISSN 1096-9926. PMID 10525206.
  36. ^ Holson, J. F; Stump, D. G; Clevidence, K. J; Knapp, J. F; Farr, C. H (2000-05-01). "Evaluation of the prenatal developmental toxicity of orally administered arsenic trioxide in rats". Food and Chemical Toxicology. 38 (5): 459–466. doi:10.1016/S0278-6915(00)00015-6. PMID 10762732.
  37. ^ Beck, B. D.; Slayton, T. M.; Farr, C. H.; Sved, D. W.; Crecelius, E. A.; Holson, J. F. (2002-04-01). "Systemic uptake of inhaled arsenic in rabbits". Human & Experimental Toxicology. 21 (4): 205–215. Bibcode:2002HETox..21..205B. doi:10.1191/0960327102ht237oa. ISSN 0960-3271. PMID 12099622. S2CID 24675062.
  38. ^ Burns-Naas, Leigh Ann; Stump, Donald G; Webber, Stephanie; Holson, Joseph F; Masarjian, Lilit; Furman, Grace; Zorbas, Mark (2003-12-01). "Absence of reproductive and developmental toxicity in rats following oral dosing with nelfinavir". Regulatory Toxicology and Pharmacology. 38 (3): 304–316. doi:10.1016/S0273-2300(03)00097-7. PMID 14623481.
  39. ^ Burns-Naas, Leigh Ann; Webber, Stephanie; Stump, Donald G; Holson, Joseph F; Masarjian, Lilit; Zorbas, Mark (2003-12-01). "Absence of embryo-fetal toxicity in rats or rabbits following oral dosing with nelfinavir". Regulatory Toxicology and Pharmacology. 38 (3): 291–303. doi:10.1016/S0273-2300(03)00096-5. PMID 14623480.
  40. ^ Hines, Ronald N.; Adams, Jane; Buck, Germaine M.; Faber, Willem; Holson, Joseph F.; Jacobson, Sandra W.; Keszler, Martin; McMartin, Kenneth; Segraves, Robert Taylor (2004-08-01). "NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of fluoxetine". Birth Defects Research Part B: Developmental and Reproductive Toxicology. 71 (4): 193–280. doi:10.1002/bdrb.20014. ISSN 1542-9741. PMID 15334524.
  41. ^ "NTP-CERHR Monograph on the Potential Human Reproductive and Developmental Effects of Fluoxetine" (PDF). Retrieved March 12, 2016.
  42. ^ Meeks, Robert G.; Stump, Donald G.; Siddiqui, Waheed H.; Holson, Joseph F.; Plotzke, Kathleen P.; Reynolds, Vincent L. (2007-02-01). "An inhalation reproductive toxicity study of octamethylcyclotetrasiloxane (D4) in female rats using multiple and single day exposure regimens". Reproductive Toxicology. 23 (2): 192–201. doi:10.1016/j.reprotox.2006.12.005. PMID 17254748.
  43. ^ Siddiqui, Waheed H.; Stump, Donald G.; Plotzke, Kathleen P.; Holson, Joseph F.; Meeks, Robert G. (2007-02-01). "A two-generation reproductive toxicity study of octamethylcyclotetrasiloxane (D4) in rats exposed by whole-body vapor inhalation". Reproductive Toxicology. 23 (2): 202–215. doi:10.1016/j.reprotox.2006.11.011. PMID 17223010.
  44. ^ Siddiqui, Waheed H.; Stump, Donald G.; Reynolds, Vincent L.; Plotzke, Kathleen P.; Holson, Joseph F.; Meeks, Robert G. (2007-02-01). "A two-generation reproductive toxicity study of decamethylcyclopentasiloxane (D5) in rats exposed by whole-body vapor inhalation". Reproductive Toxicology. 23 (2): 216–225. doi:10.1016/j.reprotox.2006.11.006. PMID 17175135.
  45. ^ Nemec, Mark; Sloter, Eddie; Stump, Donald; Holson, Joseph; Kinzell, John (2009). "Prenatal developmental toxicity studies of inhaled methyl iodide vapor in rabbits reveal a susceptible window of exposure inducing late gestational fetotoxicity". Inhalation Toxicology. 21 (6): 449–461. Bibcode:2009InhTx..21..449N. doi:10.1080/08958370802596876. PMID 19519146. S2CID 24014318.
  46. ^ Sloter, Eddie; Nemec, Mark; Stump, Donald; Holson, Joseph; Kirkpatrick, Daniel; Gargas, Michael; Kinzell, John (2009). "D. Kirkpatrick, M. Gargas, J. Kinzell, Methyl iodide-induced fetal hypothyroidism implicated in late-stage fetal death in rabbits". Inhalation Toxicology. 21 (6): 462–479. doi:10.1080/08958370802596942. PMID 19519147. S2CID 37726507.
  47. ^ Holson, Joseph F.; Stump, Donald G.; Pearce, L. Bruce; Watson, Rebecca E.; DeSesso, John M. (2005-01-01). "Mode of Action: Yolk Sac Poisoning and Impeded Histiotrophic Nutrition—HBOC-Related Congenital Malformations". Critical Reviews in Toxicology. 35 (8–9): 739–745. doi:10.1080/10408440591007412. ISSN 1040-8444. PMID 16417041. S2CID 31900464.
  48. ^ Holson, J. F.; Stump, D. G.; Pearce, L. B.; Watson, R. E.; DeSesso, J. M. (2015-04-01). "Absence of developmental toxicity in a canine model after infusion of a hemoglobin-based oxygen carrier: Implications for risk assessment". Reproductive Toxicology. 52: 101–107. doi:10.1016/j.reprotox.2015.01.006. PMID 25697570.
  49. ^ Stump, D. G.; Holson, J. F.; Harris, C.; Pearce, L. B.; Watson, R. E.; DeSesso, J. M. (2015-04-01). "Developmental toxicity in rats of a hemoglobin-based oxygen carrier results from impeded function of the inverted visceral yolk sac". Reproductive Toxicology. 52: 108–117. doi:10.1016/j.reprotox.2015.01.005. PMC 7127137. PMID 25617809.
  50. ^ "Holson v. WRH, Inc. et al". govinfo. United States Government Publishing Office (GPO). Retrieved 23 March 2020.
  51. ^ "Holson and Pepper appeals to withdraw pleas denied". www.times-gazette.com. Retrieved 2020-03-23.
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Joseph_F._Holson&oldid=1259651398"